Cancer research test targets tumor-suppressor protein, 1/14
January 2014—Spring Bioscience has added the Anti-PTEN (SP218) rabbit monoclonal immunohistochemistry antibody to its portfolio of antibodies for cancer research.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
ICE COLD-PCR analysis presented, 1/14
January 2014—Transgenomic in October announced the results of a research collaboration with MD Anderson Cancer Center employing the company’s ICE COLD-PCR platform. This interim analysis demonstrates that in a high percentage of patients with advanced cancers, the same genetic mutations were detected in cell-free DNA present in the blood as were originally found in primary tumors. In a subset of patients followed over time, detection of mutations in cfDNA correlated with response to therapy or disease progression.
Freezerworks Unlimited upgrade, 1/14
January 2014—Dataworks Development released an upgrade, version 6.0, to its Freezerworks Unlimited freezer inventory and sample management software program. Expanded configurability in version 6.0 is most notable with improvements and greater capabilities in screen design and layout, as well as in adapting the shipping processes to the workflow of the lab, biobank, and repository. The report writer has been redesigned to offer a more user-friendly interface for developing and printing reports, while adding flexibility for subtotaling and inventory counts. Users can also bar code any data field on a report for quick and accurate accessing of sample records and data.
MPLN acquires MiSeqDx, 1/14
January 2014—Molecular Pathology Laboratory Network has acquired the Illumina MiSeqDx and will use the system to expand testing across all of its clinical laboratories, including its clinical trials group Geneuity Clinical Research Services. MPLN is a molecular reference laboratory specializing in oncology, women’s health, and clinical research services.
Epigenomics’ biomarker shows promising results in clinical study, 1/14
January 2014—Epigenomics announced the results from a clinical study that showed methylated SHOX2 to be a sensitive and specific biomarker for therapy monitoring and early detection of tumor response in lung cancer patients.
Favorable results for CINtec PLUS cytology test, 1/14
January 2014—Ventana Medical Systems announced the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute (Ikenberg H, et al. 2013;105[20]:1550–1557).
nCounter Dx Analysis, 1/14
January 2014—NanoString Technologies launched its nCounter Dx Analysis System for high-complexity, CLIA-certified laboratories. The nCounter Dx Analysis System is the only platform 510(k) cleared by the FDA to run the Prosigna Prognostic Breast Cancer Gene Signature Assay.
Genetic profile for patients with DLBCL, 1/14
January 2014—Diagnovus announced an addition to its Engauge cancer assay portfolio with the launch of the Engauge-cancer DLBCL Gene Panel, a genomic profile to aid physicians in tailoring treatment specifically for patients with diffuse large B-cell lymphoma.
CLSI EP26 guideline, 1/14
January 2014—The Clinical and Laboratory Standards Institute has published a new document, “EP26-A–User Evaluation of Between-Reagent Lot Variation; Approved Guideline.”
Miraca acquires PLUS, 1/14
January 2014—Miraca Life Sciences (MLS) has acquired PLUS Diagnostics from Water Street Healthcare Partners. MLS provides diagnostic services in dermatology, gastroenterology, hematology, and urology.